Background {#section1-1534735419832358}
==========

Exercise interventions are known to positively influence physical and psychological health of cancer patients,^[@bibr1-1534735419832358][@bibr2-1534735419832358]-[@bibr3-1534735419832358]^ even in patients undergoing chemotherapy.^[@bibr4-1534735419832358]^ In patients with hematological malignancies^[@bibr5-1534735419832358][@bibr6-1534735419832358][@bibr7-1534735419832358][@bibr8-1534735419832358]-[@bibr9-1534735419832358]^ as well as in patients with Down syndrome (DS),^[@bibr10-1534735419832358]^ feasibility and safety of physical activity programs have also been validated. This is highly relevant because the incidence of leukemia in people with DS is significantly elevated compared with people without DS and has been estimated to occur 20 to 30 times more frequently.^[@bibr11-1534735419832358][@bibr12-1534735419832358][@bibr13-1534735419832358]-[@bibr14-1534735419832358]^ To the best of our knowledge, exercise programs with cancer patients have not included people with DS. Consequently, this population has been excluded from exercise programs, probably because of safety considerations. Against this backdrop, we evaluated the feasibility and safety of an exercise intervention in a 22-year-old man with DS who was undergoing high-dose chemotherapy for acute lymphoblastic leukemia.

Case Presentation {#section2-1534735419832358}
=================

Participant {#section3-1534735419832358}
-----------

The participant investigated here had to be excluded from an ongoing clinical trial^[@bibr15-1534735419832358]^ because DS was an exclusion criterion. To follow the United Nations Convention on the Rights of Persons with Disabilities and to facilitate access to the exercise intervention, we included the patient in this case report.

Physician's approval and parental consent were received prior to intervention. Further inclusion criteria were age above 18 years and no current symptoms of coronary illness or orthopedic disease, which would contraindicate cycling. The patient was 22 years of age and 161 cm tall and had an initial weight of 60 kg; thus, body mass index at baseline was 24.7 kg.m^2^. Type of trisomy 21 was a nondisjunction trisomy, and intellectual disability was mild to moderate according to patient's family and opinion of involved study personal. Leukemia was classified as Ph/BCR-ABL-negative common-B-ALL. Hypothyroidism, which was treated by daily medication of [l]{.smallcaps}-thyroxin, preexisted, as did a moderate mitral and tricuspid valve insufficiency. In addition, prior to being hospitalized because of the leukemia diagnosis, a gastric infection was detected and still persisted during the intervention. The leukemia disease was treated according to the GMALL 08/13-protocol (EudraCT Number: 2013-003466-13). Before being diagnosed with leukemia, the participant worked in a disabled workshop as a gardener and waiter. Concerning physical activity, he reported attending a dance theater with 1 to 2 hours training a week for about 1 year.

Exercise Intervention {#section4-1534735419832358}
---------------------

In addition to usual clinical care, the study participant received an exercise program 3 times per week over a 5-week period, targeting 30 minutes per session. The intervention began about 10 days after starting the first phase of induction therapy in the hospital and about 4 weeks after the first diagnosis of leukemia. Each session was supervised by a sports science student (LB). The individual program included aerobic endurance training on a cycle ergometer as well as autogenic training modified for people with cognitive impairments.^[@bibr16-1534735419832358]^ Blood pressure-- and heart rate (HR)-monitored ergometer training consisted of a 5-minute warm-up, an exercise period targeting 20 minutes at an intensity of 70% to 80% of HR~max~, and a 5-minute cooldown. After finishing an exercise session, the rate of perceived exertion (RPE) was documented to gain feedback on exercise intensity. The cycling sessions were stopped early if the patient wished to do so. If there were any complications present, such as anemia (hemoglobin \< 7 g/dL), thrombocytopenia (platelets \< 10 000/µL), no medical approval, or ongoing infusions, or if the patient was feeling generally unwell, autogenic training was carried out instead of cycling. All exercise sessions and blood status were tracked in a training log.

Assessments {#section5-1534735419832358}
-----------

The participant was examined at 3 time points (*t*~0~: preintervention, at the start of high-dose chemotherapy; *t*~1~: postintervention; *t*~2~: 2 weeks postintervention). At each time point, endurance performance was tested on the cycle ergometer using a modified World Health Organization schema for oncological patients.^[@bibr7-1534735419832358],[@bibr17-1534735419832358]^ The protocol started at 20 W, and performance increased by 10 W every minute until voluntary exhaustion. The test was terminated early in case of dizziness, nausea, shortness of breath, chest pain, or blood pressure values \>250/110 mm Hg. The patient was advised to cycle at about 70 rpm. Additionally, at each stage of the cycling protocol, RPE and HR were assessed. Fatigue was evaluated with the Multidimensional Fatigue Inventory-20 (MFI-20) questionnaire^[@bibr18-1534735419832358]^ via face-to-face interview with one of the investigators (LB).

Results {#section6-1534735419832358}
=======

The study participant was able to complete all training sessions (11× ergometer and 6× autogenic training, adherence 100%; [Figure 1](#fig1-1534735419832358){ref-type="fig"}). Autogenic training was carried out after ergometer training for motivational purposes twice ([Figure 1](#fig1-1534735419832358){ref-type="fig"}). Duration of autogenic training ranged from 15 to 30 minutes because formats were different.^[@bibr16-1534735419832358]^ The targeted duration on the cycle ergometer could not be reached (mean = 13 minutes, range = 6.5-16; [Figure 1](#fig1-1534735419832358){ref-type="fig"}). On 5 occasions, the exercise session was stopped early by the patient because of difficulties, including dizziness, gastric pain, headache, or muscle ache. However, no serious adverse events occurred, even when exercising immediately after infusion of chemotherapy (see [Table 1](#table1-1534735419832358){ref-type="table"} for a complete overview of medical treatment in relation to training sessions). Results of physical performance and the MFI-20 are shown in [Figures 2A](#fig2-1534735419832358){ref-type="fig"} and [2B](#fig2-1534735419832358){ref-type="fig"}. Overall, except for the scale of reduced motivation, no further increase in fatigue could be observed from *t*~0~ to *t*~1~. However, 2 weeks postintervention (*t*~2~), most subscales reincreased toward baseline levels (*t*~0~). Endurance performance testing at *t*~0~ was stopped early by the participant before physical exhaustion because of dizziness. Thus, an invalid performance testing resulted (see [Figure 2A](#fig2-1534735419832358){ref-type="fig"}). Therefore, intensity for ergometer training was calculated using the following formula: 200 − Age × (0.7-0.8).^[@bibr19-1534735419832358]^ Reasons to terminate the endurance testing at *t*~1~ were gastric pain and dizziness combined with decreased blood pressure. Similar to *t*~0~, complications were related to the leukemia disease and not to the existence of trisomy. At *t*~2~, the participant was able to reach his subjective performance maximum (RPE 19). Of note, bodyweight decreased from 60 kg at baseline to 54 kg at *t*~1~ and 52 kg at *t*~2~.

![Number and duration of training sessions.](10.1177_1534735419832358-fig1){#fig1-1534735419832358}

###### 

Details of Treatment.

![](10.1177_1534735419832358-table1)

  Phase                           Induction I               Induction II                    Induction II                     Post-induction                                                                                                                                                                                                                                                                                                                            
  ------------------------------- ------------------------- ------------------------------- -------------------------------- ---------------------------------- --------------------------------------------- ------------------ ------------------------------- ---------------------------- ---------------------------- ---------------- ------------------------- ---------------------------- ---------------------------- -------------------------------------- -----------
  Hemoglobin (g/dL)               8.1                       8.6                             8.3                              8.2                                8.3                                           8.1                Not evaluated                   8.7                          10                           8.4              Not evaluated             9.1                          10                           9.7                                    7.7
  Thrombocytes (/µL)              40 000                    47 000                          48 000                           102 000                            147 000                                       265 000            Not evaluated                   230 000                      130 000                      24 000           Not evaluated             31 000                       36 000                       27 000                                 41 000
  Day of GMALL protocol           18                        20                              21                               22                                 23                                            24                 30                              33                           35                           37               38                        40                           43                           44                                     47
  Treatment                       None                      Vincristine, PEG-asparaginase   None                             None                               Antibody                                      Cyclophosphamide   None                            Cytarabine, mercaptopurine   Cytarabine, mercaptopurine   Mercaptopurine   Mercaptopurine            Cytarabine, mercaptopurine   Cytarabine, mercaptopurine   Antibody, cytarabine, mercaptopurine   None
  Reasons for AT                  Gastric pain, exhausted                                   Gastric pain, ongoing infusion                                      Ongoing infusion, pain (bone marrow biopsy)   Motivation                                         Gastric pain, dizziness                                   Motivation                                                                                                                                  
  Reasons for shortened session                                                             Dizziness                        Dizziness, headache, tachycardia                                                 Gastric pain       Dizziness, loss of motivation                                                                              Gastric pain, dizziness   Exhausted                    Exhausted                    Muscle ache, exhausted                 exhausted

Abbreviation: AT, autogenic training.

![Results of physical endurance testing and MFI-20 across all measurement time-points.\
Abbreviation: RPE, rate of perceived exertion; Hfmax, maximal heart frequency.](10.1177_1534735419832358-fig2){#fig2-1534735419832358}

Discussion {#section7-1534735419832358}
==========

This study examined whether an exercise intervention is feasible in a man with DS suffering from acute lymphoblastic leukemia and whether potential benefits in fatigue and physical performance exist.

The exercise intervention was feasible and well accepted by the participant, reflected in an adherence rate of 100%. In addition, family members and clinical staff reported after the intervention that the participant kept asking for the training sessions. We suppose that the individual coaching and the good relation with the supervisor (LB) was helpful for adherence. The assumption is supported by results from Wilde et al,^[@bibr20-1534735419832358]^ who showed higher active behavior for people with DS when they were receiving higher amounts of attention or had intensified interaction with another person. Although both aspects are present in individual coaching, it must be mentioned that the Wilde et al^[@bibr20-1534735419832358]^ study included children with DS and examined a behavior of playing---not the participation in an intervention program. Furthermore, we think that it was not only the type of coaching that was helpful for adherence, but also the multimodal program adapted to the patient's daily condition. Rapid changes in health condition is a problem of exercise therapy in patients with hematological malignancies, especially during induction chemotherapy.^[@bibr21-1534735419832358]^ Degree of adherence in this study was higher compared with a physical activity intervention in patients suffering from acute leukemia.^[@bibr8-1534735419832358]^ When considering adherence in this study without the alternative of autogenic training, compliance is comparable to the study by Bryant et al,^[@bibr8-1534735419832358]^ who did not integrate relaxation techniques in their program. Thus, autogenic training as a relaxion technique might be an adequate way to enhance compliance of leukemia patients in physical activity programs. In addition, there is evidence of moderate positive effects of relaxation training in cancer patients^[@bibr22-1534735419832358]^ as well as in people with cognitive impairments.^[@bibr23-1534735419832358]^ High rates of adherence in people with DS have also been reported in the literature. However, these studies have mostly centered on a walking program.^[@bibr24-1534735419832358],[@bibr25-1534735419832358]^

In contrast to feasibility of the training sessions, physical endurance testing was not feasible. Neither a high level in RPE nor a HR near HR~max~ could be reached ([Figure 2](#fig2-1534735419832358){ref-type="fig"}). This was also the case when accounting for a lower predicted HR~max~ because of chronotropic incompetence in people with DS.^[@bibr26-1534735419832358][@bibr27-1534735419832358][@bibr28-1534735419832358][@bibr29-1534735419832358]-[@bibr30-1534735419832358]^ Better outcomes of endurance testing at *t*~2~ might be explained by the termination of chemotherapy treatment 1 week prior, resulting in a better condition of the patient. Even though the testing procedure used is recommended for cancer patients,^[@bibr17-1534735419832358]^ at this point, studies applying this strenuous testing method on patients suffering from acute lymphoblastic leukemia and DS were not found in the literature. In addition, the testing procedure used might be regarded as too intense, if one keeps in mind different cardiorespiratory, cardiovascular, and metabolic characteristics of people with DS (eg, lower fitness, HR~peak~, chronotropic incompetence, or VO~2max~).^[@bibr27-1534735419832358][@bibr28-1534735419832358][@bibr29-1534735419832358][@bibr30-1534735419832358]-[@bibr31-1534735419832358]^ Consequently, submaximum performance testing similar to the 6-minute walk test, which is recommended for weak oncological patients^[@bibr17-1534735419832358]^ and which has previously been shown to be feasible in leukemia patients^[@bibr31-1534735419832358]^ and people with DS^[@bibr25-1534735419832358],[@bibr32-1534735419832358]^ should be used instead. Another option might be treadmill exercise testing because it seems to be valid and reliable in people with DS.^[@bibr33-1534735419832358]^ Overall, a valid endurance assessment is needed and indispensable for adequate training.

Even if the alternative calculation of the HR for training prescription seems to be an adequate method for acute leukemia patients for moderate and high intensities,^[@bibr33-1534735419832358]^ there are several other formulas for prescription in the literature. For example, the German Cancer Aid Society^[@bibr34-1534735419832358]^ suggests a formula of 180 − Age ± 10 bpm, with the tendency to be lower than 150 bpm for leukemia patients, whereas Baumann^[@bibr35-1534735419832358]^ recommends a HR of 180 − (Age × 0.8) for people suffering from acute leukemia, especially while undergoing chemotherapy. The targeted HR while exercising was about 11 bpm higher in this case report when compared with that of Baumann.^[@bibr35-1534735419832358]^ In addition, these calculations as well as the formula used in this study do not account for the different cardiovascular characteristics of people with DS.^[@bibr27-1534735419832358][@bibr28-1534735419832358][@bibr29-1534735419832358][@bibr30-1534735419832358]-[@bibr31-1534735419832358]^ According to Fernhall et al,^[@bibr27-1534735419832358]^ the peak HR in people with DS is about 30 bpm lower than the one predicted by the standard formula of 220 − Age. When subtracting 20 bpm because of training on the cycling ergometer,^[@bibr19-1534735419832358]^ a difference of about 10 bpm results. This difference is equal to the difference from the formula of Baumann.^[@bibr35-1534735419832358]^ Consequently, the exercise intensity could have been too high for the participant, resulting in the observed shortened ergometer training periods, whereas the average RPE of 13.9 during the ergometer training contradicts this assumption. Nonetheless, the application of a formula to identify an adequate HR for people with DS or exercising with lower intensity, in intervals or separated into more sessions per day, might be more satisfying and could lead to longer exercise periods in the future.

Lacking adequate testing of endurance capacity, no clear statement on changes in physical performance can be made. Still, it is observable that the participant needed less alternative autogenic training in the latter phase of the intervention, resulting in a more stable participation and training period on the cycling ergometer (training sessions 9-15; see [Figure 1](#fig1-1534735419832358){ref-type="fig"}). Apart from cardiovascular function, improvements may be attributable to a better economy and coordination of cycling. Similarly, Millar et al^[@bibr32-1534735419832358]^ suggested a better walking economy for observed improvements in walking distance and walking endurance in people with DS without a change in cardiovascular function. However, existing studies in both patients with acute leukemia^[@bibr6-1534735419832358],[@bibr31-1534735419832358],[@bibr36-1534735419832358]^ and people with DS^[@bibr37-1534735419832358]^ have reported improvements in physical performance after a physical activity program, albeit with substantial differences in the applied exercise protocols. In patients with acute leukemia, exercising on a cycling ergometer is common because it is well controlled and has a reduced risk for injuries.^[@bibr17-1534735419832358],[@bibr35-1534735419832358],[@bibr38-1534735419832358]^ On the other hand, walking programs are more established in people with DS.^[@bibr37-1534735419832358]^ Additionally, according to the review by Dodd and Shields,^[@bibr37-1534735419832358]^ an intervention should last for about 12 to 16 weeks with 3 weekly sessions to gain positive effects in fitness of people with DS. Thus, the shorter intervention period in this study resulting from the protocol of chemotherapy and the hospital setting could have been a limiting factor for improvements in physical performance. Nevertheless, no serious decrease in endurance capacity could be observed, supporting the assumption of a potential benefit of the intervention because the (passive) control groups of other exercise intervention studies in similar settings^[@bibr6-1534735419832358],[@bibr8-1534735419832358],[@bibr31-1534735419832358],[@bibr32-1534735419832358]^ did decline.

Unfortunately, the MFI-20 has not been validated in people with DS yet, but the study participant seems to be similarly affected by fatigue compared with other cancer patients^[@bibr18-1534735419832358]^ (see [Figure 2B](#fig2-1534735419832358){ref-type="fig"}). In contrast to the increase in reduced motivation of the MFI-20 at *t*~1~ the rate of participation in the intervention does not indicate a decreased motivation (see [Figure 1](#fig1-1534735419832358){ref-type="fig"}). The stable overall fatigue at *t*~1~ and the resurgence at *t*~2~ (2 weeks postintervention) might support a potential benefit of the program, if one considers that other cancer patients show a pronounced increase in degree of fatigue while undergoing chemotherapy without an exercise intervention.^[@bibr39-1534735419832358]^ Nonetheless, regarding studies including patients with acute leukemia, several cases of decrease in fatigue have been observed while exercising, but no significant results were reported in the meta-analysis by Zhou et al.^[@bibr31-1534735419832358]^ However, it has to be acknowledged that this meta-analysis had a small number of included studies with small sample sizes. Besides, the high adherence might have influenced the maintenance in level of overall fatigue. According to Schulz et al,^[@bibr1-1534735419832358]^ good adherence is related to a positive effect on fatigue.

Conclusion {#section8-1534735419832358}
==========

Exercise, except for testing of maximum endurance capacity, was feasible and well accepted by the leukemia patient with DS. Similar to physical activity interventions in leukemia patients without DS^[@bibr7-1534735419832358]^ and other studies with DS,^[@bibr37-1534735419832358]^ no unexpected withdrawal or superior negative effects occurred, supporting the safety of the program. Furthermore, the results of the assessments allow us to assume that the intervention was helpful to counteract a further increase in fatigue as well as a further decrease in physical endurance. Therefore, we recommend that exercise interventions should also be offered to people with DS while suffering from acute leukemia. This is especially important when considering the higher rate of incidence of leukemia in people with DS and the inferior prognosis for this cancer population.^[@bibr13-1534735419832358],[@bibr40-1534735419832358],[@bibr41-1534735419832358]^ Overall, because of the study design and the applied assessments, these findings need to be interpreted cautiously and further examined in randomized controlled trials. In addition, it seems like the program needs to be further adapted to this special patient group (eg, modified HR intensities, exercising in intervals, longer duration of intervention, testing of walking distance). Nevertheless, this case report is a first step toward finding an adequate and effective intervention.
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